1. Home
  2. LBRT vs MESO Comparison

LBRT vs MESO Comparison

Compare LBRT & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LBRT
  • MESO
  • Stock Information
  • Founded
  • LBRT 2011
  • MESO 2004
  • Country
  • LBRT United States
  • MESO Australia
  • Employees
  • LBRT N/A
  • MESO N/A
  • Industry
  • LBRT Oilfield Services/Equipment
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • LBRT Energy
  • MESO Health Care
  • Exchange
  • LBRT Nasdaq
  • MESO Nasdaq
  • Market Cap
  • LBRT 1.8B
  • MESO 1.8B
  • IPO Year
  • LBRT 2018
  • MESO N/A
  • Fundamental
  • Price
  • LBRT $16.69
  • MESO $15.49
  • Analyst Decision
  • LBRT Buy
  • MESO Buy
  • Analyst Count
  • LBRT 10
  • MESO 2
  • Target Price
  • LBRT $16.00
  • MESO $24.00
  • AVG Volume (30 Days)
  • LBRT 4.5M
  • MESO 155.5K
  • Earning Date
  • LBRT 10-16-2025
  • MESO 08-28-2025
  • Dividend Yield
  • LBRT 2.20%
  • MESO N/A
  • EPS Growth
  • LBRT N/A
  • MESO N/A
  • EPS
  • LBRT 1.13
  • MESO N/A
  • Revenue
  • LBRT $3,910,953,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • LBRT N/A
  • MESO N/A
  • Revenue Next Year
  • LBRT N/A
  • MESO N/A
  • P/E Ratio
  • LBRT $14.53
  • MESO N/A
  • Revenue Growth
  • LBRT N/A
  • MESO 191.39
  • 52 Week Low
  • LBRT $9.50
  • MESO $9.61
  • 52 Week High
  • LBRT $23.58
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • LBRT 54.80
  • MESO 48.85
  • Support Level
  • LBRT $15.70
  • MESO $14.32
  • Resistance Level
  • LBRT $17.78
  • MESO $15.62
  • Average True Range (ATR)
  • LBRT 1.00
  • MESO 0.54
  • MACD
  • LBRT -0.21
  • MESO 0.03
  • Stochastic Oscillator
  • LBRT 60.62
  • MESO 85.26

About LBRT Liberty Energy Inc.

Liberty Energy Inc is a integrated energy services and technology company focused on providing hydraulic fracturing services and related technologies to onshore oil and natural gas exploration and production (E&P) companies. The Company offers customers with hydraulic fracturing services, together with complementary services including wireline services, proppant delivery solutions, field gas processing and treating, compressed natural gas (CNG) delivery, data analytics, related goods (including sand mine operations), and technologies to facilitate lower emission completions, thereby helping customers reduce emissions profile. The company provides services across USA and Canada.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: